In its upcoming report, Genuine Parts (GPC) is predicted by Wall Street analysts to post quarterly earnings of $1.54 per share, reflecting a decline of 31.9% compared to the same period last year. Revenues are forecasted to be $5.69 billion, representing a year-over-year increase of 1.9%.The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates duri ...

The market expects Genuine Parts (GPC) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 18, 2025, might help the stock move higher if these key numbers ...

Group 1 - Genuine Parts Company plans to release its fourth quarter and full-year financial results on February 18, 2025 [1] - Following the financial results release, management will host a conference call at 8:30 a.m. ET, accessible via webcast and phone [1] - The company has a vast network of over 10,700 locations across 17 countries, supported by more than 60,000 employees [2] Group 2 - Established in 1928, Genuine Parts Company is a leading global service provider of automotive and industrial replacement parts [2] - The Automotive Parts Group operates in multiple countries including the U.S., Canada, Mexico, and several European nations [2] - The Industrial Parts Group serves customers primarily in the U.S., Canada, Mexico, and Australasia [2]

GPC ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Genuine Parts Company ...

Core Insights - Carisma Therapeutics has announced positive pre-clinical data for its anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC), developed in collaboration with Moderna [1][2][3] Group 1: Therapy Development - The anti-GPC3 CAR-M therapy demonstrates specificity for the GPC3 tumor antigen, showing potent dose-dependent cytotoxicity against GPC3+ tumor cells [2] - Systemic administration of the therapy significantly reduced tumor burden and suppressed liver metastasis in both syngeneic and humanized tumor models [2] - The therapy was well tolerated in mouse models, indicating its potential as an off-the-shelf treatment for GPC3+ solid tumors, including HCC [2] Group 2: Technological Innovation - The therapy utilizes mRNA/LNP technology to generate anti-GPC3 CAR-M cells directly in vivo, leading to significant tumor reduction in relevant pre-clinical models [3] - The successful application of the mRNA/LNP platform highlights its potential in enabling in vivo cell therapy [3] Group 3: Company Overview - Carisma Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies using its proprietary macrophage and monocyte cell engineering platform [4]

Core Insights - Carisma Therapeutics Inc. announced new pre-clinical data on its anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC), developed in collaboration with Moderna, to be presented at the SITC Annual Meeting on November 8, 2024 [1][2][3] Company Overview - Carisma Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies, particularly utilizing engineered macrophages and monocytes to treat cancer and other serious diseases [5] Research and Development Highlights - The pre-clinical data indicates that the anti-GPC3 CAR-M therapy shows robust anti-tumor activity and represents a novel off-the-shelf approach for treating GPC3+ solid tumors, including HCC [2][3] - The therapy employs lipid nanoparticles to deliver mRNA encoding CARs, reprogramming endogenous myeloid cells in vivo [2] Presentation Details - The poster session at SITC will include the abstract titled "Pre-Clinical Efficacy of a Novel Anti-GPC3 In Vivo CAR-M for Hepatocellular Carcinoma," with publication number 329, scheduled for November 8, 2024 [4]

If you have found my strategies interesting, useful, or profitable, consider supporting my continued research by joining the Cyclical Investor's Club . It's only $400/year, and it's where I share my latest research and exclusive small-and-midcap ideas. Two-week trials are free. All stock investing is about risk vs. reward over time. If an investor isn't estimating the likely reward over a given time frame, like 5 or 10 years, and then comparing that to the inflation-adjusted risk over Cory leads the investi ...

Have you evaluated the performance of Genuine Parts' (GPC) international operations for the quarter ending September 2024? Given the extensive global presence of this auto and industrial parts distributor, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth. In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth jour ...

Shares fell after the company lowered 2024 earnings expectations.Genuine Parts (GPC -2.59%) shares fell hard this week after the global automotive and industrial parts giant reported some discouraging news about its short-term operating trends. The stock fell 20% through early Thursday trading, according to S&P Global Market Intelligence, compared to a modest decline for the S&P 500 index.That performance gap was due to Genuine Parts' Q3 earnings update, which showed surprisingly weak sales and profit trend ...

SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility, today announced an update regarding its clinic trial plans. The Company received regulatory approval from the Israeli Ministry of Health in July 2024 and subsequent institutional review board clearance to initiate patient enrollment in up to 7 academic centers for its c ...